Štandardný Diagnostický a Terapeutický Postup na Komplexný Manažment Pacienta so Stabilnou Koronárnou Chorobou Srdca

Objectives

This Slovak standard diagnostic and therapeutic procedure, effective from 1 May 2020, provides a comprehensive evidence-based framework for the prevention, diagnosis, treatment, secondary prevention and long-term management of stable coronary heart disease. Its central aims are to relieve angina, prevent cardiovascular events and sudden cardiac death, improve prognosis and quality of life, and enable patients to participate actively in managing their health.[1][2][3][4][5]

• Strengthen lifelong control of modifiable cardiovascular risks, including dyslipidaemia, hypertension, smoking, diabetes mellitus, obesity, metabolic syndrome and physical inactivity, while recognising genetic susceptibility to premature coronary heart disease.[6][7]
• Promote non-smoking, regular dynamic physical activity, weight management, diets lower in animal fats and salt, and greater consumption of fruit, vegetables and fresh fish.[6][3]
• Increase health literacy through lifelong education at population, community and individual levels, including education on disease, risk factors, medicines, treatment strategy and when to seek care.[6][8][9][4]
• Stratify suspected disease by clinical pre-test probability and prognosis, using symptoms, demographic characteristics, left-ventricular function, ischaemia testing and coronary anatomy to select appropriate non-invasive or invasive management.[10][11][12]
• Provide optimal medical treatment for confirmed stable coronary heart disease, tailoring anti-anginal and preventive medicines to symptoms, comorbidities, blood pressure, heart rate and tolerability.[11][8][13]
• Use revascularisation to improve prognosis in significant coronary disease or extensive ischaemia and to relieve limiting angina that persists despite pharmacological treatment.[14]
• Address coronary microvascular dysfunction and vasospastic angina in patients with anginal symptoms despite normal or non-significantly diseased coronary arteries.[15][16]
• Adapt treatment decisions for older people and for patients with kidney disease, diabetes or other comorbidities, accounting for disease severity, procedural risks and patient preferences.[17][18][19]

Implementation

The procedure uses a stepped, multidisciplinary pathway spanning primary care, specialist assessment, cardiology services and specialised centres. It combines clinical assessment, risk-based testing, lifestyle support, pharmacotherapy, revascularisation where indicated, structured follow-up and periodic quality review, while allowing documented evidence-based departures from the standard pathway for individual clinical circumstances.[2][10][20][4][5]

• Enable general practitioners and paediatricians to distinguish possible cardiac symptoms from vertebrogenic and other non-cardiac causes, identify the need for specialist assessment and refer patients with relevant clinical documentation.[2]
• Assign general practitioners responsibility for secondary prevention, lifestyle change, authorised prescribing, monitoring of adverse effects and discontinuation, and consultation with specialists for patients with confirmed stable disease.[2]
• Assign cardiologists or internists responsibility for the diagnostic and therapeutic pathway, specialist investigations, clinical follow-up, laboratory tests, electrocardiography and imaging; refer selected patients to specialised cardiology centres for differential diagnosis, catheter-based treatment and, where necessary, cardiac-surgical consultation.[2]
• Use multidisciplinary input when required from neurology, diabetology, metabolic or nutritional services, angiology, pulmonology, orthopaedics and other specialties, with potential involvement of nurses, social workers and clinical psychologists.[2]
• Begin assessment with a detailed history, physical examination, electrocardiography and laboratory testing. Use resting echocardiography to assess ventricular function, regional abnormalities, diastolic function and alternative causes, while recognising that a normal electrocardiogram does not exclude coronary heart disease.[21][22][23][24]
• Apply clinical pre-test probability categories of below 15%, 15% to 85%, and above 85% to guide investigation. Focus low-probability cases on extracardiac causes, use non-invasive stress testing for intermediate probability, and treat high probability as confirmed disease.[11]
• Use exercise testing or stress imaging according to clinical suitability, local availability and expertise; consider computed tomography coronary angiography, stress echocardiography, nuclear perfusion imaging or cardiac magnetic resonance imaging where exercise testing is infeasible, inconclusive or inappropriate.[25][26][24]
• Use invasive coronary angiography, including fractional flow reserve where necessary, for unstable or worsening disease, positive biomarkers, abnormal imaging, severe angina, high-risk profiles, contradictory non-invasive tests or assessment for revascularisation.[24][27]
• Provide anti-anginal treatment alongside secondary prevention, using short-acting nitrates for symptom relief and beta-blockers and/or calcium-channel blockers as first-line options; consider other medicines where symptoms persist or treatment is not tolerated.[8]
• Initiate non-pharmacological and pharmacological secondary prevention during hospitalisation after revascularisation, educate patients before discharge, and provide regular outpatient follow-up including review of symptoms and antiplatelet treatment.[28][29]
• Coordinate follow-up between general practitioners and cardiologists. Conduct reviews every four to six months during the first treatment year, with intervals potentially extended thereafter, and repeat electrocardiography annually or when clinical status or treatment changes.[20]
• Monitor blood pressure, pulse, adherence, risk factors, clinical status, laboratory results and treatment tolerability at consultations; inform the health insurer and patient if adequate adherence is not achieved within three months of treatment initiation.[30][7][9]
• Review the standard procedure after one year and then every five years, or earlier when relevant evidence or Slovak implementation experience warrants revision; add clinical-audit and patient-safety tools at the first revision.[4]
• Assess access to non-invasive diagnostics, revascularisation facilities and specialist care, and monitor treatment indicators including lipid control, blood-pressure control, antiplatelet therapy, indicated heart-failure medicines and smoking status.[4][31]

Monitoring & Evaluation

Monitoring combines patient-level clinical follow-up, diagnostic reassessment, treatment-adherence checks and a planned guideline audit cycle. It does not establish a comprehensive national surveillance or reporting system beyond these clinical and quality-review mechanisms.[20][4][31]

• Review outpatients every four to six months in the first year after therapy begins, with possible extension of the interval by one year; include clinical history and biochemical tests where appropriate.[20]
• Perform annual resting electrocardiography and repeat it when clinical status changes, angina or arrhythmia-related symptoms emerge, or treatment changes may affect cardiac conduction.[20]
• Use exercise testing or stress imaging for recurrent or new symptoms and suspected instability; consider renewed prognostic testing for asymptomatic patients after the prior test’s validity period, including exercise testing after at least two years if clinical status is unchanged.[20]
• Monitor clinical cardiac status through laboratory testing, electrocardiography and relevant imaging, escalating care to higher-level cardiology services when the patient’s condition changes.[2]
• Repeat lipid parameters, glucose-metabolism measures and creatinine annually in all patients with stable coronary heart disease; monitor electrolytes for patients using angiotensin-converting enzyme inhibitors or diuretics, and measure creatine kinase in statin users with symptoms of myopathy.[23]
• Review uncomplicated asymptomatic patients annually and more complicated or symptomatic patients at least twice yearly, with electrocardiography and laboratory investigations; assess blood pressure and pulse at every visit.[30][7]
• Use echocardiography every four to five years for asymptomatic patients with good left-ventricular systolic function, and annually or more frequently for substantially reduced function according to clinical status.[7]
• Assess adherence to lifelong therapy at every consultation; if adequate adherence is not achieved within three months of treatment initiation, inform both the patient’s health insurer and the patient.[9]
• Monitor long-term cardiovascular risk factors, including smoking, diet, physical activity, body weight, lipid parameters, blood pressure and blood glucose.[3]
• Assess treatment response shortly after pharmacological therapy starts and use symptoms, tolerability, coronary anatomy, ventricular function and ischaemia extent to guide treatment and revascularisation decisions.[8][14]
• Use one-year mortality for prognostic stratification, defining low risk as below 1%, intermediate risk as above 1% but below 3%, and high risk as above 3%.[12]
• Apply specified follow-up thresholds after revascularisation: optimise pharmacotherapy when ischaemia affects less than 5% of the myocardium and recommend coronary angiography when it affects more than 10%.[32]
• Use delayed stress imaging at six months to detect in-stent restenosis or stent-graft occlusion where considered appropriate, while avoiding routine early or delayed angiographic surveillance after percutaneous coronary intervention except in selected high-risk procedures.[32]
• Classify clinical recommendations using European Society of Cardiology recommendation classes and grade evidence from Level A, based on multiple randomised trials or meta-analyses, to Level C, based on consensus, smaller studies or registries.[33][6]
• Audit and review the standard procedure after one year, then every five years or earlier when relevant evidence becomes available and Slovak implementation permits; add clinical-audit and patient-safety tools at the first revision.[4]
• Assess organisational access through timely availability of non-invasive diagnostics, revascularisation facilities, and cardiologists or internists.[4]
• Monitor quality indicators covering low-density lipoprotein cholesterol management, blood-pressure control, antiplatelet use, indicated beta-blocker and renin-angiotensin-system treatment, and smoking cessation or non-smoking.[31]
• Record any justified departure from the standard clinical procedure in the patient’s health documentation.[5]

Costing & Financing

Financial information is limited. Development and administrative support came through grants under the Operational Programme Human Resources of the Ministry of Labour, Social Affairs and Family of the Slovak Republic, but no grant values are reported.[34]

• Support development and introduction of innovative standard clinical procedures into medical practice through an identified grant mechanism.[34]
• Support development and introduction of prevention procedures into medical practice through a separate identified grant mechanism.[34]
• Consider patient bonus schemes through health insurance funds to encourage self-management and attendance at required preventive examinations; the text does not specify financing, eligibility, incentive values or budgets.[31]
• Note that the source does not provide implementation budgets, recurrent service costs, allocations for diagnostics or revascularisation, funding gaps, resource-mobilisation plans, unit costs, or economic assumptions.[34][4][31]